0000000000630549

AUTHOR

Sue Richards

showing 2 related works from this author

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

2021

Summary Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence. Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligib…

Malemedicine.medical_specialtyTime FactorsTime Factormedicine.medical_treatmentCarotid StenosiMEDLINECarotid endarterectomyRate ratioRisk AssessmentAsymptomaticlaw.inventionRandomized controlled triallawRisk Factorscarotid artery stenting (CAS); carotid endarterectomy (CEA)StentmedicineHumansCarotid StenosisStrokeEndarterectomyAgedEndarterectomy Carotidbusiness.industrycarotid arteryRisk FactorArticlesGeneral Medicinetrialmedicine.diseaseSettore MED/22 - CHIRURGIA VASCOLARESurgeryStrokeStenosisTreatment Outcomecarotid artery stenting (CAS)Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleStentsHuman medicinemedicine.symptomcarotid endarterectomy (CEA)businessHumanLancet (London, England)
researchProduct

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT …

2010

Abstract Abstract 877 This phase-III randomized EBMT-intergroup trial studied the impact of a consolidating autoHSCT vs no consolidation for patients with CLL in Binet stage A progressive, B or C , in CR, nodular PR or VGPR after first or second line therapy. The primary objective was to show that autoHSCT increased the 5-year progression-free survival (PFS) by 30%. Although it had been calculated that 270 patients were to be randomized, the study was terminated by the steering committee in July 2007 due to poor accrual. Here we present a first analysis based on 69% of expected follow-up forms. Results: Between November 2001 and July 2007, 223 patients were enrolled (SFGM-TC/FCLLG n=98, MRC…

medicine.medical_specialtyDisease statusRandomizationbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)ImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrySurgerylaw.inventionRandomized controlled triallawInternal medicinemedicineIn patientProgression-free survivalStage (cooking)business
researchProduct